Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S383000, C514S422000, C548S311700, C548S266400, C548S526000
Reexamination Certificate
active
10525410
ABSTRACT:
The present invention provides benzodifuran imidazoline derivatives and benzofuran imidazoline derivatives for lowering intraocular pressure and providing ocular neuroprotection.
REFERENCES:
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5494928 (1996-02-01), Bös
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5891131 (1999-04-01), Rajan et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6660870 (2003-12-01), Ruskinko et al.
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6806285 (2004-10-01), May et al.
patent: 6884816 (2005-04-01), May et al.
patent: 2003/0181503 (2003-09-01), May et al.
patent: 2036975 (1991-08-01), None
patent: 0 771 563 (2003-01-01), None
patent: 323985 (1966-12-01), None
patent: WO 92/00338 (1992-01-01), None
patent: WO 94/03162 (1994-02-01), None
patent: WO 97/35579 (1997-10-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 01/40183 (2001-06-01), None
patent: WO 01/70207 (2001-09-01), None
patent: WO 01/70223 (2001-09-01), None
patent: WO 01/70230 (2001-09-01), None
patent: WO 01/70701 (2001-09-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
patent: WO 02/098350 (2002-12-01), None
patent: WO 02/098400 (2002-12-01), None
patent: WO 02/098860 (2002-12-01), None
patent: WO 03/051291 (2003-06-01), None
patent: WO 03/051352 (2003-06-01), None
patent: WO 03/053436 (2003-07-01), None
patent: WO 2004/019874 (2004-03-01), None
patent: WO 2004/028451 (2004-04-01), None
patent: WO 2004/054572 (2004-07-01), None
patent: WO 2004/058725 (2004-07-01), None
Levin, Leonard, “Neuroprotection in neuro-ophthalmic disease”, 2000, Neuro-ophthalmology, 24, p. 383-386.
Obach, R. Scott, “Drug-drug interactions”, 2003, Drugs of Today, 39(5), p. 301-311.
Boudier et al., “Structure Activity Relationships for Central and Peripheral Alpha Adrenergic Activities of Imidazoline Derivatives,”Life Sciences, vol. 17, pp. 377-386 (1975).
Bowen et al., “Nonlinear regression using spreadsheets,”Trends in Pharmacological Sciences, vol. 16, pp. 413-417 (1995).
Bradford et al., “A Rapid and Sensitive Method for the Quantitaion of Mircorgam Quantities of Protein Utilizing the Principle of Protein-Dye Binding,”Analytical Biochemistry, vol. 72, pp. 248-254 (1976).
Chambers et al., Enantiospecific Synthesis and Pharmacological Evaluaion of a Series of Super-Potent, Conformationally Restricted 5-HT2A2CReceptor Agonists,J. Med. Chem., vol. 44, pp. 1003-1010 (2001).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. of Ocular Pharmacology, vol. 1(2), pp. 137-147 (1985).
De Vry et al., “Characterization of the Aminomethylchroman Derivative BAY×3702 as a Highly Potent 5-Hydroxytryptamine1AReceptor Agonist,”J. of Pharmacology and Experimental Therapeutics, vol. 284 (3), pp. 1082-1094 (1998).
Florella et al., “The role ofo the 5-HT2Aand 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion,”Psychopharmacology, vol. 121, pp. 364-372 (1995).
Griffin et al., “Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization,”J. of Pharmacology and Experimental Therapeutics, vol. 286(1), pp. 411-418 (1998).
Gupta et al., “Therapeutic Potentials of 5-HT Receptor Modulators,”Indian J. of Pharmacology, vol. 26, pp. 94-107 (1994).
Hoyer et al., VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin),Pharmacological Reviews, vol. 46(2), pp. 157-203 (1994).
Johnson et al., Binding to the Serotonin 5-HT2Receptor by the Enantiomers of125I-DOI,Neuropharmacology, vol. 26(12), pp. 1803-1806 (1987).
Krootila et al., “Effect of Serotonin and its Antagonist (Ketanserin) in Intraocular Pressure in the Rabbit,”J. of Ocular Pharmacology, vol. 3(4), pp. 279-290 (1987).
Lopez-Rodriguez, “Synthesis and Structure-Activity Relationships of a New Model of Arylpiperazines. 4.1-(ω-(4-Arylpiperazine-1-yl)alkyl]-3-(diphenylmethylene)-2,5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2,5-pyrrolidinediones:Study of the Steric Requirements of the Terminal Amide Fragment on 5-HT1AAffinity/Selectivity,” J. Med. Chem., 42(1):36-49 (1999).
Mallorga et al., “Characterization of serotonin receptors in the iris+ciliary body of the albino rabbit,”Current Eye Research, vol. 6(3), pp. 527-532 (1987).
Martin et al., “The Structure and Signalling Properties of 5-HT Receptors: an endless diversity?”Trends in Pharmaceutical Sciences, vol. 19, pp. 2-4 (1998).
Mano et al., “The Effect of Anplag (Sarpogelate HCL), New Selective 5-HT2Antagonist on Intraocular Pressure in Rabbits,”IOVS,vol. 36(4), S719 (1995).
May et al., “A Novel and Selective 5-HT2Receptor Agonist with Ocular Hypotensive Activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole,”J. Med. Chem., vol. 46, pp. 4188-4195 (2003).
May et al., “Evaluation of the Ocular Hypotensive Response of Serotonin 5-HT1Aand 5-HT2Receptor Ligands in Conscious Ocular Hypertensive Cynomolgus Monkeys,”J. of Pharmacology and Experimental Therapeutics, vol. 306(1), pp. 301-309 (2003).
Monte et al, “Dihydrobenzofuran Analogues of Hallucinogens. 31Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigiddified Methoxy Groups,”J. Med. Chem., vol. 39, pp. 2953-2961 (1996).
Morin et al, “A Method to Measure Simultaneously Cyclic AMP and Inositol Phosphate Accumulationin Rat Brain Slices,”J. Of Neurochemistry, vol. 56(4), pp. 1114-1120 (1991).
Osborne et al., “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?”,Ophthalmologica, vol. 210, pp. 308-314 (1996).
Osborne et al., “5-Hydroxytryptamine1Aagonists: potential use in glaucoma. Evidence from animal studies,”Eye, vol. 14(38), pp. 454-463 (2000).
Salomon et al., “Adenylate Cyclase Assay,”Advances in Cyclic Nucleotide Research, vol. 10, pp. 35-55 (1979).
Salomon et al., “[2] Cellular Responsiveness to Hormones and Neurotransmitters: Conversion of [3H]Adenine to [3H]cAMP in Cell Monolayers, Cell Suspensions, and Tissue Slices,”Methods in Enzymology, vol. 195, pp. 22-28 (1991).
Schoeffter et al., “Inhibition of cAMP Accumulation Via Recombinant Human Serotonin 5-HT1AReceptors: Considerations on Receptor Effector Coupling across Systems,”Neuropharmacology, vol. 36(4/5), pp. 429-437 (1997).
Sharif et al., “[3H]AL-5848 ([3H]9β-(+)-Fluprostenol). Carboxylic Acid of Travoprost (AL-6221), a Novel FP Prostaglandin o Study the Pharmacology and Autoradiographic Localization of the FP Receptor,”J. Pharm. Pharmacol.vol. 51: pp. 685-694 (1999).
Takeda et al., “The Effect of Inplag. Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,” IOVS, Vo. 36(4), S734 (1995).
Tobin et al., “Evidence for the Presence of Serotonergic Nerves and Receptors in the Iris-Ciliary Body Complex of the Rabbit,”The J. of Neurosciences, v
Feng Zixia
Hellberg Mark R.
Alcon Inc.
Cheng Karen
McKane Joseph K.
Ryan Patrick M.
LandOfFree
Benzodifuranimidazoline and benzofuranimidazoline... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzodifuranimidazoline and benzofuranimidazoline..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodifuranimidazoline and benzofuranimidazoline... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746372